EGOT and breast carcinoma: More importantly, breast cancer patients with high expression of EGOT achieved a higher complete pathological response ratio than patients with low expression of EGOT when treated with paclitaxel-containing adjuvant chemotherapy regimens in the HMUCC cohort (Fig. 6h).